Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03443024 · ClinicalTrials.gov registry record · Phase 2
A Study of Lebrikizumab (LY3650150) in Participants With Moderate-to-Severe Atopic Dermatitis
A Phase 2 study of Atopic Dermatitis, sponsored by Eli Lilly and Company.
- Completed
- Registry status
- Phase 2
- Development phase
- 280
- Enrollment target
- 20
- Study locations
NCT03443024: Completed Phase 2 study of Atopic Dermatitis, sponsored by Eli Lilly and Company.
NCT03443024 is a Phase 2 study of Atopic Dermatitis that has completed, run by Eli Lilly and Company. The registered enrollment target is 280 participants, below the 608-participant average among 150 other Atopic Dermatitis trials with a reported enrollment target (54% lower). The trial reports 20 study locations across 6 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03443024, a Phase 2 study of Atopic Dermatitis, has completed, sponsored by Eli Lilly and Company.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 280 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to evaluate the safety and efficacy of lebrikizumab compared with placebo in participants with moderate-to-severe atopic dermatitis.
Primary Outcome
The EASI assesses objective physician estimates of 2 dimensions of atopic dermatitis - disease extent and clinical signs affected: 0 = 0%; 1 = 1-9%; 2 = 10-29%; 3 = 30-49%; 4 = 50-69%; 5 = 70-89%; 6 = 90-100% and the severity of 4 clinical signs: (1) erythema, (2) edema/papulation, (3) excoriation, and (4) lichenification each on a scale of 0 to 3 (0 = none, absent; 1 = mild; 2 = moderate; 3 = severe) at 4 body sites (head/neck, trunk, upper limbs, and lower limbs). Half scores are allowed betwe
Conditions Studied
Interventions
- DRUG Placebo
- BIOLOGICAL Lebrikizumab
Study Locations (20)
California
- Center for Dermatology Clinical Research, Inc. - Fremont
- University of Southern California - Los Angeles
- Dermatology Research Associates - Los Angeles
- Stanford Medicine Outpatient Center-Medical Dermatology Clinic - Redwood City
- Center for Dermatology and Laser Surgery - Sacramento
- UCSD Dermatology - San Diego
- TCR Medical Corporation - San Diego
- Clinical Science Institute - Santa Monica
Florida
- Total Vein and Skin - Boynton Beach
- Florida Academic Centers Research and Education, LLC - Coral Gables
- Olympian Clinical Research - Largo
- Tory Sullivan, MD PA - North Miami Beach
- International Clinical Research - US, LLC - Sanford
- Integrated Clinical Research, LLC - West Palm Beach
Arkansas
- Dermatology Trial Associates - Bryant
- Northwest Arkansas Clinical Trials Center - Rogers
Georgia
- Marietta Dermatology Clinical Research, Inc. - Marietta
- Advanced Medical Research, PC - Sandy Springs
Arizona
- Clear Dermatology & Aesthetics Center - Scottsdale
District of Columbia
- George Washington Medical Faculty Associates - Washington D.C.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 280 participants |
| Start Date | 2018-01-30 |
| Est. Completion | 2019-05-23 |
| Phase | Phase 2 |
What the finished NCT03443024 record still lists
NCT03443024 is an interventional study that assigns participants to a tested intervention. The registered 280 participants enrollment target is mid-sized for trials with a published cap, below the 608-participant average among 150 other Atopic Dermatitis trials with a reported enrollment target (54% lower).
The record links to 1 condition, with Atopic Dermatitis appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT03443024 names 20 study sites across 6 states, led by California, Florida, Arkansas.
Frequently Asked Questions
What is clinical trial NCT03443024 about?
NCT03443024 is a clinical study titled "A Study of Lebrikizumab (LY3650150) in Participants With Moderate-to-Severe Atopic Dermatitis". The purpose of this study is to evaluate the safety and efficacy of lebrikizumab compared with placebo in participants with moderate-to-severe atopic dermatitis.
What is the current status of trial NCT03443024?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 280 participants. The study started on 2018-01-30. Estimated completion is 2019-05-23.
What conditions does trial NCT03443024 study?
This clinical trial studies the following conditions: Atopic Dermatitis.
What interventions are being tested in trial NCT03443024?
The interventions under investigation include: Placebo (DRUG), Lebrikizumab (BIOLOGICAL).
Who is sponsoring clinical trial NCT03443024?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03443024 being conducted?
This trial has 20 study locations across Arizona, Arkansas, California, District of Columbia, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Atopic Dermatitis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03443024's enrollment target sits among peer trials
280 44th of 150 higher than 107 of 150 other Atopic Dermatitis trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Atopic Dermatitis trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study to Evaluate the Efficacy and Safety of IMG-007 in Adult Participants With Moderate-to-Severe Atopic Dermatitis
RECRUITING · Phase 2
-
Cardamom and Topical Roseomonas in Atopic Dermatitis
RECRUITING · Phase 2
-
A Study to Assess the Efficacy and Safety of Afimkibart (RO7790121) in Participants With Moderate to Severe Atopic Dermatitis
RECRUITING · Phase 2
-
Evaluate Efficacy and Safety of Repeat Subcutaneous Doses of FB825 in Adults With Moderate-to-Severe Atopic Dermatitis
RECRUITING · Phase 2
-
A Study Evaluating TRIV-509 in Atopic Dermatitis
RECRUITING · Phase 2
-
A Study to Assess Molecular Changes in Adult Participants With Moderate to Severe Hidradenitis Suppurativa or With Moderate to Severe Atopic Dermatitis Receiving Subcutaneous Injections of Lutikizumab
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04084730 · 280 participants · Phase 2
Study of 3-Day Partial Breast Radiation Therapy in Women With Breast Cancer
- NCT04518657 · 280 participants · NA
Internet-Delivered Lifestyle Physical Activity Intervention for Cognitive Processing Speed in Multiple Sclerosis
- NCT04634916 · 280 participants · NA
Post-market Surveillance Study of the BD® WavelinQ™ EndoAVF System
- NCT04829617 · 280 participants · NA
Promoting Well-being and Health in Heart Failure
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI